Updated Covid Vaccines: Staying Ahead of the Variant Curve

Abstract This article explores the 2024–2025 coronavirus disease-2019 (COVID-19) vaccines targeting new variants, including KP. 2, KP. 3, and JN.1. As breakthrough infections increase, these updated vaccines aim to restore waning immunity, particularly in high-risk groups. We assess the evolution of key variants like delta and omicron, their impact on immune evasion, and the effectiveness of bivalent and monovalent vaccines. Future strategies may include mucosal vaccines and annual boosters tailored to circulating variants, emphasizing the need for ongoing research and monitoring to enhance community protection against COVID-19.